China has slashed the price of dozens of top drugs from multinationals such as Roche, GlaxoSmithKline and AstraZeneca by as much as 70 per cent as a condition of adding them to a government health insurance scheme.
中國促使羅氏(Roche)、葛蘭素史克(GSK)和阿斯特捷利康(AstraZeneca)等跨國公司將數十種重點藥品降價,其中降幅最高的達到70%,以此爲條件將這些藥品納入政府醫保藥品目錄。
您已閱讀11%(306字),剩餘89%(2536字)包含更多重要資訊,訂閱以繼續探索完整內容,並享受更多專屬服務。